1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN FC FRAGMENT), DIMER
Juvenile Idiopathic Arthritis
Explore 14 assets in Juvenile Idiopathic Arthritis →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Duke University
Modality
protein_peptide
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04585711CT.gov Pharmacokinetics and Pharmacodynamics of Biologic Drugs in Obese Patients With Arthritis | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Juvenile Idiopathic Arthritis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| 1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN FC FRAGMENT), DIMER (this asset) | Duke University | P1 | CC · 43 |
| Cyclophosphamide | Paul Szabolcs | P2 | CCC |
| Nivestim | Paul Szabolcs | P2 | CCC |
| Melphalan | Paul Szabolcs | P2 | CCC |
| Moderna Covid-19 Vaccine Rna | National Institute of Allergy and Infectious Diseases (NIAID) | P2 | CCC |
| Fludarabine | Paul Szabolcs | P2 | CCC |
| Thiotepa | Paul Szabolcs | P2 | CCC |
| Jnj-78436735 | National Institute of Allergy and Infectious Diseases (NIAID) | P2 | CCC |
| Monovalent [B.1.351] Cov2 Pres Dtm-As03 | National Institute of Allergy and Infectious Diseases (NIAID) | P2 | CCC |
+10 more in the Juvenile Idiopathic Arthritis cohort
Other indications for 1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN FC FRAGMENT), DIMER
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Psoriasis | — | P4 | BBB · 76 |
| Skin Carcinoma | — | P4 | BB · 67 |
| Sciatica | — | P2/3 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. 1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN FC FRAGMENT), DIMER in Juvenile Idiopathic Arthritis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/1-235-tumor-necrosis-factor-receptor-human-fusion-protein-with-236-467-immunoglobulin-g1-human-gamma1-chain-fc-fragment-dimer-juvenile-idiopathic-arthritis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →